An all-oral combination of metronomic cyclophosphamide plus capecitabine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: a phase II study
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
An all-oral combination of metronomic cyclophosphamide plus capecitabine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: a phase II study
Authors
Keywords
-
Journal
CANCER CHEMOTHERAPY AND PHARMACOLOGY
Volume 69, Issue 2, Pages 515-522
Publisher
Springer Nature
Online
2011-08-26
DOI
10.1007/s00280-011-1728-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Simple oral therapy with capecitabine (CAPE) and cyclophosphamide (CPA) for metastatic breast cancer (MBC).
- (2017) A. F. Schott et al. JOURNAL OF CLINICAL ONCOLOGY
- RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer
- (2011) Nicholas J. Robert et al. JOURNAL OF CLINICAL ONCOLOGY
- Gemcitabine and capecitabine in combination for advanced anthracycline and taxane pre-treated breast cancer patients: A phase II study
- (2010) Annika Malmström et al. ACTA ONCOLOGICA
- Oral combination chemotherapy with capecitabine and cyclophosphamide in patients with metastatic breast cancer: a phase II study
- (2010) Maki Tanaka et al. ANTI-CANCER DRUGS
- RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab In Combination with Chemotherapy for Second-Line Treatment of HER2-Negative Metastatic Breast Cancer.
- (2010) A. Brufsky et al. CANCER RESEARCH
- Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes
- (2009) Alison Jones et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A Phase II trial of the combination of vinorelbine and capecitabine as second-line treatment in metastatic breast cancer previously treated with taxanes and/or anthracyclines
- (2009) George Orphanos et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Trastuzumab Beyond Progression in Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: A German Breast Group 26/Breast International Group 03-05 Study
- (2009) Gunter von Minckwitz et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase I/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines
- (2008) P. Schmid et al. ANNALS OF ONCOLOGY
- Impact, mechanisms, and novel chemotherapy strategies for overcoming resistance to anthracyclines and taxanes in metastatic breast cancer
- (2008) Edith A. Perez BREAST CANCER RESEARCH AND TREATMENT
- Phase II study of capecitabine and trastuzumab combination chemotherapy in patients with HER2 overexpressing metastatic breast cancers resistant to both anthracyclines and taxanes
- (2008) Takanori Ishida et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Capecitabine and Cisplatin Combination Is an Active and Well-Tolerated Doublet in the Treatment of Metastatic Breast Carcinoma Patients Pretreated with Anthracycline and Taxanes
- (2008) Berna Öksüzoglu et al. CHEMOTHERAPY
- A Phase II Study of Capecitabine and Vinorelbine in Patients with Metastatic Breast Cancer Pretreated with Anthracyclines and Taxanes
- (2008) Laura G. Estévez et al. Clinical Breast Cancer
- Daily low-dose/continuous capecitabine combined with neo-adjuvant irradiation reduces VEGF and PDGF-BB levels in rectal carcinoma patients
- (2007) David Loven et al. ACTA ONCOLOGICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation